Page URL: https://www.bionews.org.uk/page_89283

Haemophilia gene therapy trial stopped

7 June 2004
By BioNews
Appeared in BioNews 261

A US biotechnology firm announced last week that it is discontinuing its haemophilia trial, citing technical and safety reasons. Avigen said that it was stopping the trial so it could concentrate on neurological diseases, but it also said that the gene therapy treatment for haemophilia faced 'certain scientific, regulatory and clinical hurdles'.

The company is trying to develop new treatments for haemophilia B, a blood clotting disorder caused by the lack of a crucial protein called Factor IX. Avigen aimed to replace this missing protein by using a virus to deliver the Factor IX gene into a liver artery. The treatment has already proved successful in dogs affected by the disorder. However, Avigen halted the human trial after two of the seven patients developed mild side effects. Both participants had slightly raised levels of liver enzymes, which suggests that the virus used, an adeno-associated virus (AAV), triggered an immune response in the body.

Study leaders Mark Kay and Katherine High hope that they can modify the trial, and carry on testing the therapy. 'In terms of the science, I think things are going pretty well', High told the journal Science. Kay says the first step is to confirm that the AAV gene delivery system did trigger the immune response, and then perhaps to start another trial, in which patients are treated briefly with immunosuppressive drugs at the same time as the gene therapy treatment.

Gene therapy researchers say that Avigen's decision to stop the trial isn't a major setback to the field, because the safety problem was minor, and seems to be specific to the haemophilia trial. Some other trials are also using AAVs to deliver genes, but most are injecting small doses into particular tissues, rather than arteries. This approach is less likely to trigger side effects, says US gene therapy expert Savio Woo.

The US National Haemophilia Foundation (NHF) remains optimistic about the potential for gene transfer for haemophilia, and says it will continue to fund such research. 'This is a time to redouble our efforts to support promising research so that breakthroughs for haemophilia and all genetic diseases will happen sooner rather than later', said NHF president Richard Metz.

SOURCES & REFERENCES
Company discontinues trial of hemophilia gene therapy
The New York Times |  28 May 2004
National Hemophilia Foundation Not Deterred by Biotech Announcement
Yahoo Daily News |  28 May 2004
Side effects sideline hemophilia trial
Science |  4 June 2004
RELATED ARTICLES FROM THE BIONEWS ARCHIVE
11 July 2011 - by Dr Caroline Hirst 
Scientists have, for the first time, successfully treated a blood disorder by repairing errors in the DNA of a living animal. Researchers from The Children’s Hospital of Philadelphia, together with California-based Sangamo BioSciences, have applied an innovative genome editing technique to treat haemophilia B, which affects around one in 30,000 boys and men...
9 June 2003 - by BioNews 
A type of virus used to deliver genes to the body in gene therapy treatments could cause cell defects that may lead to cancer, according to a new US study. The findings, published in this month's Nature Genetics, follow news earlier this year that a second patient in a gene...
18 February 2002 - by BioNews 
Doctors have successfully used gene therapy in the treatment for a type of haemophilia, a condition caused by a defect in one of the genes which controls blood clotting. Sufferers bruise easily, are prone to nosebleeds, and have a risk of internal bleeding. A virus that had been genetically altered...
HAVE YOUR SAY
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions


Syndicate this story - click here to enquire about using this story.